



ANATARA
LIFESCIENCES

Annual General Meeting

15 November 2016



Disclaimer


The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.



Key Financial Details

ASX Code ANR	Market Capitalisation \$54.4 million	Share Price¹ \$1.10
Current Cash² \$13.8 million	Ordinary Shares 49,413,236	Share Price up 162% since IPO

1. As at 14 November 2016
2. Appendix 4E - 30 June 2016



ANR Share Price Chart



Oral therapeutics for gastrointestinal disease in livestock and humans

Detach™

- Natural, safe, non-antibiotic therapeutic that prevents and treats gastrointestinal diseases, including diarrhoea
- Meets the need to reduce the use of antibiotics in animal production
- Unlike antibiotics, Detach™ will not contribute to antimicrobial resistance



Need to combat antimicrobial resistance

resistance to antibiotics ‘....*the greatest and most urgent global risk*’

General Assembly of the United Nations 2016


Antibiotic resistance driven by the overuse of antibiotics

- **10 million:** the number of people who will die every year due to AMR by 2050
- **\$100 trillion,** the estimated total GDP that will be lost globally by 2050 if AMR isn't tackled



Lead Indication – Pigs

Diarrhoea affects hundreds of millions of piglets born each year



Millions of piglets weaned per year

20% more piglets die before weaning due to health issues

Market Opportunity is clear

- Detach™ addresses a major need – the livestock industry need effective alternatives to antibiotics to prevent diarrhoea
- Global animal antibiotic market valued at ~ \$4.6 billion in 2014¹. Production animals 70%. Pigs lead by market share of 25%.
- Pork is #1 consumed meat in the world
- Global demand for meat is rising. More than 85% more meat needed by 2030².
- Governments are banning antibiotics for growth promotion and restricting prophylactic use in animal production
- Consumers want their meat to be safe
- Retailers are pledging to offer '*antibiotic free*' meat



FY16 – Key Achievements

Milestone

Partnering


Zoetis have exclusive worldwide right (excl. AU/NZ) to evaluate Detach™ for veterinary use in livestock

Animal safety trials

Detach™ proven safe in piglets even when administered at 5x and more frequent than the recommended dose

Submission of dossier to APVMA

Anatara's application for registration of Detach was lodged with the APVMA (post reporting period).



Detach™

Poised for swift market entry

Commercially validated, supported by demand

- A clear path to market: Launch in 2017
 - Proven efficacy on commercial pig farms (therapeutic claims)
 - Proven safety (active ingredient is GRAS)
 - Manufacturing complete at commercial scale and global supply confirmed
- Introduction of Detach™ is supported by industry, government, retailer & consumer demand
- Commercially validated
- Detach™ will be supplied in Australia via pre-existing distribution channels (Australian pork industry is heavily consolidated)



Current 50 kg scale
(≈500,000 doses)



1,000 kg capacity
(≈8,500,000 doses)






ANATARA
LIFESCIENCES

Human Applications


There are 4 billion episodes of diarrhoea in the world annually.

Diarrhoea is the second cause of death in children under 5 years, and the leading cause of malnutrition.



Detach™ from Pigs to People

Anatara's commercialisation strategy



Detach™
- From Pigs
to People

- Same mechanism of action for treatment of disease in pigs and humans
- Pre-clinical program for animals complete therefore development for humans de-risked
- Clinic ready (CMC, Toxicology, Pharmacology well developed)
- Ready to Partner/Develop



Anatara technology – for humans

- Detach™ technology to treat human gastrointestinal conditions, such as:
 - Inflammatory bowel disease and
 - Irritable bowel syndrome
 - Traveller's Diarrhoea
- Significant unmet need not addressed by current products



Human gastro related disorders/disease



Traveller's diarrhoea

50 million
travellers at risk per year.
Rising to 100 million by 2020.



TD is a threat to military efficiency and preventative treatment is a priority for the US Army



Developing countries

#2 cause of death in under 5's
(1.3 million kids per year.)



United States of America



~ 211-375m episodes of diarrhoea p.a.
116m people use anti-diarrhoea medication (31%).



Detach™ for Humans

Status

- Mode of action clearly understood, based on decades of research
- Pre-clinical efficacy database is very strong due to leverage of Detach™ data from pig studies
- Proof of concept in several animal models
- Confirmed efficacy in rabbit models with human diarrhoea pathogens
- Proof of concept in mouse model of inflammatory bowel disease
- Margin of safety studies (1x, 3x and 5x dose) in piglets completed (TAS study)
- Human Safety studies (Phase I) in healthy volunteers completed
 - 28 day treatment was very well tolerated



Thank you

Anatara's naturally derived substances offer a safe but effective alternative to antibiotics for gastrointestinal diseases and the Company is uniquely positioned to fulfil a currently unmet need in the huge, global animal health market.

Dr Mel Bridges, CEO & Chairman, Anatara Lifesciences

Dr Mel Bridges, CEO, Chairman & Co-founder
mbridges@anataralifesciences.com
+61 413 051 600

Dr Tracey Mynott, CSO & Co-founder
tmynott@anataralifesciences.com
+61 405 050 113

